A randomized, double-blind comparison of atomoxetine hydrochloride augmented with either extended-release methylphenidate hydrochloride (Concerta) or placebo in children with attention-deficit/hyperactivity disorder (ADHD) who have not responded to stimulant mono therapy

Trial Profile

A randomized, double-blind comparison of atomoxetine hydrochloride augmented with either extended-release methylphenidate hydrochloride (Concerta) or placebo in children with attention-deficit/hyperactivity disorder (ADHD) who have not responded to stimulant mono therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2007

At a glance

  • Drugs Atomoxetine; Methylphenidate
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 20 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top